Regeneron Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Regeneron Pharmaceuticals Inc 公司

公司簡介

公司代碼REGN

公司名稱Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

成立日期1988

CEODr. Leonard S. Schleifer, M.D., Ph.D

員工數量15106

證券類型Ordinary Share

年結日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編10591

電話17813705000

網址https://www.regeneron.com/

公司代碼REGN

上市日期Apr 02, 1991

成立日期1988

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.44K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.39K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Mr. George L. Sing

Independent Director

29.90K

+0.56%

Mr. Arthur F. (Art) Ryan

Independent Director

17.67K

+0.95%

Mr. Christopher R. Fenimore

Chief Financial Officer, Senior Vice President - Finance

16.35K

+6.24%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.36K

+9.94%

名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.44K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.39K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

收入明細

單位: USD更新時間: 3月5日週三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

EYLEA

4.76B

33.56%

Sanofi

4.53B

31.90%

Bayer

1.49B

10.55%

EYLEA HD

1.20B

8.45%

Libtayo

787.30M

5.54%

Other

1.41B

9.97%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

EYLEA

4.76B

33.56%

Sanofi

4.53B

31.90%

Bayer

1.49B

10.55%

EYLEA HD

1.20B

8.45%

Libtayo

787.30M

5.54%

Other

1.41B

9.97%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.29%

JP Morgan Asset Management

4.87%

State Street Global Advisors (US)

4.49%

Other

69.32%

持股股東

股東統計

佔比

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.29%

JP Morgan Asset Management

4.87%

State Street Global Advisors (US)

4.49%

Other

69.32%

股東類型

股東統計

佔比

Investment Advisor

47.61%

Investment Advisor/Hedge Fund

32.88%

Research Firm

2.70%

Pension Fund

2.59%

Bank and Trust

2.16%

Hedge Fund

2.09%

Individual Investor

1.66%

Sovereign Wealth Fund

1.14%

Holding Company

0.08%

Other

7.04%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

2499

99.91M

92.94%

-662.36K

2024Q4

2581

100.16M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.76M

92.44%

+388.23K

2023Q4

2406

98.49M

91.94%

-617.05K

2023Q3

2358

98.79M

92.52%

-1.70M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

2022Q4

2333

99.77M

93.16%

-1.61M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.23M

8.59%

-32.54K

-0.35%

Dec 31, 2024

Fidelity Management & Research Company LLC

7.97M

7.41%

-2.07M

-20.68%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.69M

5.29%

+193.70K

+3.52%

Dec 31, 2024

JP Morgan Asset Management

5.24M

4.87%

-524.96K

-9.10%

Dec 31, 2024

State Street Global Advisors (US)

4.83M

4.49%

-70.16K

-1.43%

Dec 31, 2024

Capital International Investors

4.73M

4.4%

+1.39M

+41.55%

Dec 31, 2024

Capital World Investors

2.77M

2.58%

-1.51M

-35.34%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.42M

2.25%

+155.36K

+6.83%

Dec 31, 2024

Dodge & Cox

2.32M

2.15%

+9.38K

+0.40%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

2.19M

2.02%

+36.58K

+1.69%

Dec 31, 2024

持股ETF

更新時間: 12 小時前

機構名稱

佔比

Future Fund Active ETF

9.96%

ProShares Ultra Nasdaq Biotechnology

7.13%

Invesco Nasdaq Biotechnology ETF

6.75%

VanEck Biotech ETF

6.03%

iShares Biotechnology ETF

5.81%

Tema Oncology ETF

4.8%

Invesco Biotechnology & Genome ETF

4.36%

Tema Neuroscience and Mental Health ETF

4.03%

Franklin Genomic Advancements ETF

4.03%

iShares Genomics Immunology and Healthcare ETF

3.33%

Future Fund Active ETF

佔比9.96%

ProShares Ultra Nasdaq Biotechnology

佔比7.13%

Invesco Nasdaq Biotechnology ETF

佔比6.75%

VanEck Biotech ETF

佔比6.03%

iShares Biotechnology ETF

佔比5.81%

Tema Oncology ETF

佔比4.8%

Invesco Biotechnology & Genome ETF

佔比4.36%

Tema Neuroscience and Mental Health ETF

佔比4.03%

Franklin Genomic Advancements ETF

佔比4.03%

iShares Genomics Immunology and Healthcare ETF

佔比3.33%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Regeneron Pharmaceuticals Inc

687.150USD

Regeneron Pharmaceuticals Inc

687.150

概覽

公司